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Venous ulceration is the final outcome of lower
extremity chronic venous insufficiency in most cases.
It is a debilitating recurrent complication, with an
estimated prevalence of 0.1% to 0.2% of the popula-
tion in developed countries.1 It has been estimated
that $1 billion is spent annually in the treatment of
chronic wounds.2 In a case control study done in our
institution, the average age of patients with venous
ulcers was approximately 20 years older than those
with uncomplicated varicose veins, demonstrating, in
a multivariate analysis, that age is an independent risk
factor.3 Also, chronic lower extremity ulcers develop
in 50% to 60% of patients with premature aging syn-
dromes, such as Werner’s syndrome.4,5 Fibroblasts
isolated from Werner’s syndrome patients exhibit a
striking reduction in growth potential, with a 70%
reduction in the patient’s expected life span and pre-
mature senescence.5
The exact pathophysiologic mechanisms leading
to ulcer formation and impaired ulcer healing have
not been elucidated. In previous experiments in our
laboratory, we demonstrated that fibroblasts cul-
tured from venous ulcers have reduced growth rates
and are larger than normal fibroblasts from the ipsi-
lateral limb of the same patient.6 Reduced growth
capacity and morphologic changes are 2 well-known
traits of cellular senescence.7 The hallmark of cellu-
lar senescence is an irreversible arrest of cell prolifer-
ation and altered cell functions.8–10 The reduction in
proliferative capacity of cells from old donors and
patients with premature aging syndromes11–14 impli-
cate cellular senescence in aging and age-related
pathologies.8,9
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Purpose: A well-recognized characteristic of venous ulcers is impaired healing.
Fibroblasts cultured from venous ulcers (wound-fb) have been shown to have reduced
growth rates and are larger than normal fibroblasts (normal-fb) from the ipsilateral
limb. Reduced growth capacity and morphologic changes are 2 well-known traits of cel-
lular senescence. Other molecular changes are overexpression of matrix proteins, such as
cellular fibronectin (cFN), and enhanced activity of b -galactosidase at pH of 6.0 (senes-
cence associated b -Gal, or SA-b -Gal). Senescence, an irreversible arrest of cell prolifera-
tion with maintenance of metabolic functions, may represent in vivo aging and thus may
be related to impaired healing. 
Methods: Cultured normal-fb and wound-fb from 7 venous ulcer patients (average age,
51 years) were obtained by taking punch biopsies of the perimeter of the ulcer and from
the ipsilateral thigh of the same patient. Growth rates, SA-b -Gal activity, and level of
cFN protein (immunoblot) and message (Northern blot) were measured.
Results: In all patients, wound-fb growth rates were significantly lower than those of
normal-fb (P = .006). A higher percentage of SA-b -Gal positive cells were found in all
wound-fb (average, 6.3% vs. 0.21%; P = .016). The level of cFN, was consistently high-
er in all wound-fb tested. Also, in 4 patients, the level of cFN messenger RNA (mRNA)
was increased.
Conclusion: Fibroblasts cultured from venous ulcers exhibited characteristics associated
with senescent cells. Accumulation of senescent cell in ulcer environment may be associ-
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Senescent cells acquire altered patterns of gene
expression, remain metabolically active, and resist
apoptotic death for long periods,6 thus accumulat-
ing in vivo upon aging.15,16 Other characterized cel-
lular and molecular changes of senescence are over-
expression of the extracellular matrix protein
fibronectin7 and induction of b -galactosidase activi-
ty at a pH of 6.0 (senescence associated b -Gal activ-
ity, or SA-b -Gal).16
We hypothesized that accumulation of senescent
fibroblasts within the venous ulcer environment
plays a significant pathophysiologic role in the
mechanism associated with impaired healing of these
lesions.
METHODS
Patients
Patients with chronic venous ulcers were inter-
viewed and examined. Nine patients agreed to enroll
in the study, but only 7 completed all stages. The
severity of venous disease in enrolled patients was
determined by a trained vascular surgeon using the
guidelines prepared by the Executive Committee of
the American Venous Forum (Clinical Classification
and Grading of Chronic Venous Disease).18 Patients
in whom concomitant arterial disease was suspected,
as evidenced by absent pulses, were excluded from
the study. Patients who were taking immunosup-
pressive medication were excluded from the study.
All patients with diabetes, patients with known HIV-
positive status, and patients with active infection
were excluded. The Institutional Review Board at
Boston Medical Center approved this study, and
informed consent was obtained from all enrolled
patients.
Materials
Dulbecco’s modified Eagles’s medium (DMEM),
trypsin, and Trizol reagents were purchased from
GibcoBRL Life Technologies (Gaithersburg, Md).
Monoclonal anti-cellular fibronectin (cFN) antibody
was purchased from Sigma (St Louis, Mo). An ECL
Western blotting detection system kit was purchased
from Amersham Life Science (Arlington Heights,
Ill). Bovine calf serum (CS) was obtained from
Hyclone Laboratories (Logan, Utah). Nitrocellulose
and Nylon membranes were purchased from
Amersham (Arlington Heights, Ill), and the oligola-
beling kit was from Pharmacia LKB Biotechnology
(Piscataway, NJ). Radiolabeled nucleotide (d-CTP)
was from New England Nuclear (Boston, Mass). X-
Gal (5-bromo-4-chloro-3-indolyl b -D-galactoside)
was purchased from Sigma (St Louis, Mo).
Fibroblasts isolation and culture
A 4 mm punch biopsy specimen was obtained
from each patient from (1) the uninvolved skin of
the thigh and (2) the ulcer edge. All ulcer biopsies
were obtained from epithelialized areas. Techniques
used to isolate and culture dermal fibroblast are
described in detail elsewhere.6 In brief, biopsies were
treated with a 5-minute povidone-iodine bath, fol-
lowed by a 5-minute bath in 70% ethanol. Overnight
trypsinization was then performed at 4°C (trypsin
solution = 1 m g/mL), allowing separation of the
dermal tissue from the epidermal and adipose tissue.
The dermal tissue was isolated under sterile condi-
tions, cut sharply into 1 to 2 mm fragments, and
placed in etched plastic tissue culture dishes (Fisher).
Complete medium (CM) that consisted of DMEM
with 10% CS and antibiotic solution (penicillin,
methicillin, Fungizone, and streptomycin) was
added to support cell growth. Two fibroblast popu-
lations were then obtained, normal fibroblasts (nor-
mal-fb) and wound fibroblasts (wound-fb). Cells
were then passed into 2 separate tissue culture dish-
es (passage 1). Once 80% to 90% confluence was
reached, 1 plate was used to freeze fibroblasts using
dimethyl sulfoxide solution, and then cells were
stored at –140°C in liquid nitrogen. From the other
plate, fibroblasts were harvested and used to gener-
ate growth curves (passage 2). All other analyses
were performed on fibroblasts previously frozen
(passage 3 cells).
Growth curves
Growth curves were assessed by plating fibroblasts
at 1500 cells per plate and determining total cell num-
ber per plate, by means of a Coulter Counter, on days
7, 10, 13, and 16. A combination of Trypsin/ethyl-
enediaminetetraacetic acid (EDTA) solution was used
to detach cells from tissue culture dishes, and detach-
ment was monitored by means of light microscopy.
Trypsin/EDTA action was neutralized with media
containing 10% CS. Cells were then harvested and
transferred to plastic vials containing Isoton.
Complete harvesting of cells was reassessed by exam-
ining plates under light microscopy. Plotting total cell
number against harvesting days generated growth
curves. Growth rate was calculated by means of the
slope of a best-fit line.
Assessment of senescence in vitro
Frozen fibroblasts were thawed following stan-
dard technique and placed in 100 mm tissue culture
dishes in the presence of CM. When 80% to 90%
confluence was obtained, cells were divided in 3
groups: (1) fibroblasts plated for determination of
SA- b -GAL activity, (2) fibroblasts plated for extra-
cellular matrix protein extraction and quantification
of fibronectin protein, and (3) fibroblasts plated for
total RNA extraction to evaluate fibronectin mRNA
content.
SA- b -GAL activity. SA- b -GAL staining was
performed according to a protocol described previ-
ously. Briefly, third passage fibroblast cultures at 30%
to 50% confluence were exposed to the staining
solution (20 mg/mL X-gal in dimethylformamide;
0.2 mol/L citric acid/Na phosphate buffer, pH =
6.0; 100 mmol/L potassium ferrocyanide; 100
mmol/L potassium ferricyanide; 5 mol/L sodium
chloride; 1 mol/L magnesium chloride; and H2O)
after being fixed with 2% formaldehyde/0.2% glu-
taraldehyde in phosphate buffer saline. Plates were
incubated for 12 to 16 hours at 37°C without CO2.
Positive cells characteristically display perinuclear
precipitation of blue dye. This allows for clear iden-
tification by means of standard light microscopy.
Percentage of positive SA- b -GAL cells was deter-
mined after counting 300 to 400 cells per plate.
Fibronectin protein analysis (Western blot).
Immunoblot analysis (Western blot) for cFN was
performed after extraction of matrix proteins from
fibroblast culture dishes.
Third passage fibroblasts were allowed to achieve
89% to 90% confluence in 60 mm culture dishes.
Urea base extraction of matrix proteins was then
performed by lysing cells into 4 mol/L urea buffer
and homogenate set for 1 to 2 hours at 4°C. The
total amount of protein was quantified by means of
the Bradford protein assay technique described else-
where. Ten to 30 m g of cell lysate protein was sepa-
rated with a 7.5% sodium dodecyl sulfate-gel elec-
trophoresis. The same amount of cell lysate protein
from both wound-fb and normal-fb cultures were
loaded. Proteins were then transferred to a nitrocel-
lulose membrane. The membrane was preincubated
in 100% Blotto (5 g of nonfat dry milk in 100 mL of
PBS) for 1 hour at room temperature. This was fol-
lowed by incubation with a mouse anti-human mon-
oclonal antibody against cFN (0.2 to 1 m g/mL in
10% Blotto) at 4°C. At the end of incubation, the
membrane was washed extensively with PBS con-
taining 0.5% Tween-20, then reacted with the sec-
ondary goat anti-mouse antibody labeled with
horseradish peroxidase. Chemiluminescent reaction
with the ECL Western blotting analysis system was
used to detect fibronectin bands by means of autora-
diography, exposing membrane to Kodak X-Omat
film.
Fibronectin mRNA detection. Total RNA was
extracted from third passage fibroblasts at an 80% to
90% confluence in 60 mm culture dishes by lysing
the cells with Trizol reagent (1 mL per 60 mm dish).
The lysate was equilibrated at room temperature for
5 minutes and extracted with chloroform (0.2 mL
per 1 mL of Trizol Reagent). RNA was precipitated
by adding 0.5 mL of isopropyl alcohol per 1 mL of
Trizol reagent. Seven to 10 m g of total cellular RNA
was separated electrophoretically through 1%
agarose gel containing 2.2 mol/L formaldehyde,
blotted on a Hybond-N nylon membrane, and
immobilized by means of short ultraviolet light illu-
mination. The same amount of total RNA was
loaded from normal-fb and wound-fb. The blot was
prehybridized for 24 hours and incubated with the
specific radiolabeled fibronectin insert (2.0–3.0 ·
106 cpm/mL hybridization solution) for 24 hours.
The membranes were washed twice for 30 minutes
with 2 X standard saline citrate solution at 65°C and
then exposed to Kodak XAR-5 film.
Probe
The complementary DNA (cDNA) specific for
fibronectin was purchased from the American Type
Cell Culture. cDNA was radiolabeled with [32P]-
dCTP (specific activity: 3,000 Ci/mmol) by means
of a commercial oligolabeling kit. Ethedium bro-
mide staining of 18S RNA was used to confirm the
equal loading of RNA in each lane.
Statistical analyses
Paired Student t test was used to compare
growth rates and density of fibronectin bands from
immunoblots autoradiographs. Nonparametric sta-
tistics (Wilcoxon rank sum test) were used to com-
pare SA- b -Gal positivity. Linear regression analysis
was used to estimate the growth rate for each cell
culture. Image analysis software (Image Tools, The
University of Texas Health Science Center, San
Antonio) was used to calculate the relative integrat-
ed optical densities from scans of autoradiographs of
immunoblot and Northern blots.
RESULTS
Fibroblasts obtained from 7 patients with ulcers
were included in all phases of the study. All ulcers
were classified clinically as symptomatic clinical clas-
sification 6, according to the American Venous
Forum ad hoc committee consensus statement from
1994,18 with a mean clinical score of 12.7 (range, 11
to 17). Of the 7 patients, 4 were men and 3 were
women. The average age of the patients was 51 years
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(range, 36 to 67 years). The average duration of the
ulcers was 15 months (range, 9 to 36 months). Two
patients had documented history of deep venous
thrombosis.
Growth rates
Wound-fb growth rates were significantly lower
than normal-fb growth rates in all 7 patients (Table
I). The average growth rate for normal-fb was
31,190 cells per day vs 11,451 cells per day for
wound-fb (P = .006).
SA-b -Gal activity
SA-b -Gal activity was not detected in normal-fb
cultures, except in the case of 1 patient who had
1.5% of cells staining positive. In the wound-fb pop-
ulations, SA- b -Gal activity was detected in all
patients, and it ranged from 1% to 20%, with a mean
of 6.3% and a median of 2% (P = .016; Table II).
There was a trend toward a significant correla-
tion between the percentage of SA- b -Gal positive
cells and the differences in growth rate between nor-
mal-fb and wound-fb, with an R2 value for the best
fit line of 0.74 (Fig 1). 
Fibronectin protein and mRNA expression
Six of the 7 patient fibroblast populations were
tested. The level of fibronectin protein isolated from
all the wound-fb cultures was consistently higher
than that isolated from the corresponding normal-fb
cultures (Fig 2). This increase ranged from 1.3 to
4.4 fold with densitometry analysis, and the differ-
ences were statistically significant (P = .027; Table
III). In 4 of those patients, the level of fibronectin
mRNA was also elevated (Fig 3). 
DISCUSSION
Fibroblasts isolated from venous ulcers showed
reduced growth rates, an increase in SA-b -Gal activ-
ity, and increased production of fibronectin when
compared with normal-fb isolated from uninvolved
skin of the same patient. Increase in wound-fb size
in our laboratory has been described previously.6
These characteristics are consistent with senescence
Table I. Growth rates from normal fibroblasts (nor-
mal-fb) and fibroblasts cultured from venous ulcers
(wound-fb) calculated using the slopes of the best fit
lines given by all points of each curve. Points of each
curve were determined by counting cells on days
7,10,13, and 16 after plating 1500 cells per plate. The
growth rates are given in cells/day.
Patient Normal Ulcer
1 40,466 8,100
2 47,033 19,600
3 17,033 6,753
4 17,600 276
5 28,066 16,033
6 60,866 24,586
7 7,270 4,812
Average 31,190* 11,451
*P = .006 (comparing normal-fb vs wound-fb, using paired
Student t test).
Fig 1. Correlation between percentage of SA- b -Gal positive cells and the ratio between normal
fibroblasts (normal-fb) and fibroblasts cultured from venous ulcers (wound-fb) growth rates.
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phenotype. These findings support the theory that
accumulation of senescent fibroblast within the ulcer
microenvironment is associated with impaired heal-
ing of these lesions.
Human fibroblasts upon senescence acquire
resistance to apoptotic programmed cell death25 for
a long period, rendering them quite stable and
allowing for accumulation in tissues upon aging.16
Senescent fibroblasts have been shown to overex-
press proteolytic activity by means of an increase in
the production of enzymes such as matrix metallo-
proteinases and to underexpress protease inhibitors.
This may contribute to dermal thinning and venous
ulcer matrix breakdown, facilitating ulcer formation
and impairing the capacity for re-epithelization and
healing. 
Fig 2. Cellular fibronectin protein extracted from 80% to 90% confluent third passage fibro-
blasts isolated from venous ulcers (wound-fb) and uninvolved skin (normal-fb) of the ipsilat-
eral thigh of the same patients. Densitometry was performed on scans from immunoblot
autoradiograph using image analysis software. Results are presented in the table.
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Senescent fibroblasts also have a significant
immunoregulatory role that may affect immune cel-
lular interactions during the process of wound heal-
ing. Senescent fibroblasts overexpress interleukin 1
(IL-1),8 have a diminished proliferative response to
tumor necrosis factor (TNF)- a , and underexpress
interleukin 6 and 8 (IL-6, IL-8) after TNF-a chal-
lenge,20 all of which may alter the immunologic
mechanisms associated with tissue repair. 
Tissue fibronectin increases with age,21 and its
gene sequence has been shown to be overexpressed in
senescent and Werner’s’s syndrome human fibro-
blasts.17 This glycoprotein encourages cell-to-cell and
cell-to-substrate interactions, playing an important
role in wound healing. However, fibronectin has been
found to be an important component of pericapillary
fibrous caps associated with venous hypertension.22
The products of fibronectin degradations are strong
chemoattractants for monocytes and macrophages and
probably act to stimulate differentiation of the mono-
Fig 3. Cellular fibronectin messenger RNA (mRNA) extracted from 80% to 90% confluent
third passage fibroblasts isolated from venous ulcers (wound-fb) and uninvolved skin (normal-
fb) of the ipsilateral thigh of the same patients. Ethidium bromide labeled 18S subunit of total
RNA loaded into each lane was used to calculate the ratio between cellular fibronectin mRNA
and total RNA for purposes of comparison. Densitometry was performed on scans from
Northern blot autoradiograph and picture of ethidium bromide labeled gel using image analy-
sis software. Results are presented in table.
Table III. Demographic characteristics and ulcer
details of the patient population.
Variables
Number 7
Age 51 years (range, 36 to 67 years)
Sex 4 men, 3 women
Greater diameter (mean) 5.8 cm (range, 2 to 10 cm)
Clinical score (mean) 12.7 (range, 11 to 17)
Duration of ulcer 15 months (range, 9 to 36 months)
Table II. Percentage of cell positively stained for
SA-b -Gal activity in cultures of normal fibroblasts
(normal-fb) and fibroblasts cultured from venous
ulcers (wound-fb). 
Patient Normal Ulcer
1 0 4
2 0 2
3 0 1
4 0 20
5 0 2
6 0 2
7 1.5 13
Average 0.2 6.3
Median 0 2.0*
*P = .015 (comparing normal-fb vs. wound-fb using Wilcoxon
signed rank test).
JOURNAL OF VASCULAR SURGERY
882 Mendez et al November 1998
cyte to the activated macrophage.23 Also, age-related
increases in macrophage adhesion to fibronectin have
been found in vitro.24 Taken together, overexpression
of fibronectin by senescent fibroblasts from venous
ulcers may: (1) result in pericapillary matrix deposition
and act as a diffusion barrier; (2) promote monocyte
trapping, differentiation, and activation with proin-
flammatory consequences; and (3) provide the sub-
strate for macrophage homing within the ulcer envi-
ronment, facilitating a chronic inflammatory process.
The increase in cFN could be caused by either a more
stable or efficient glycoprotein production by senes-
cent cells or an increase in the fibronectin message at a
transcriptional level.
SA- b -Gal activity determination using X-gal
based staining is a well-established method of assess-
ing senescent fibroblasts in vitro.16 Cells from all 3
embryonic layers express SA-b -Gal upon senescence.
Still, some cells, such as adult melanocytes and seba-
ceous and eccrine gland cells, may express this activ-
ity independent of senescence or age, but overall it is
considered a good marker of senescence in human
cells such as dermal fibroblasts.16 It is unlikely that
SA-b -Gal activity is directly involved in the process
of proliferative arrest of senescent cells, and most
likely it reflects a change in cell function that invari-
ably accompanies senescence.16
Fibroblasts isolated by explant technique are by
definition cells that have the ability to replicate, and
thus they have not reached senescence. In the in-
vitro environment, as these cells proliferate they
exhaust their replicative life span, ultimately reaching
senescence. At any given time, the proportion of cells
that reached senescence within a particular cell pop-
ulation is dependent on the replicative “age” of those
cells at the time of biopsy. The greater the number of
fibroblasts closer to replicative senescence in vivo, the
greater the number of cells that will reach senescence
upon culture in vitro at any given time. In our expe-
rience, we determined the percentage of SA- b -Gal
positive cells when third passage fibroblasts reached
approximately 50% confluency in 60 mm tissue cul-
ture dishes (approximately 3 to 4 weeks after the
biopsy specimen was taken). At this endpoint, a mean
of 6.3% (median, 2%) of wound-fb had reached
senescence vs. a mean of 0.2% (median, 0%) of nor-
mal-fb. The logical conclusion is that a greater pro-
portion of dermal fibroblasts from the ulcer biopsy
specimens was closer to replicative senescence than
fibroblasts from normal skin biopsy specimens.
As previously stated, replicative senescence is
dependent upon cumulative cell divisions and not
chronologic or metabolic time, indicating that pro-
liferation is limited by a “mitotic clock.”26,27 This
mitotic clock has been recently characterized as the
length of chromosomal telomeres and the extension
of life span achieved through elongation of telo-
meres after introduction of telomerase into normal
human fibroblasts.28
We can then speculate that inflammation, infec-
tion, or injury may locally promote accumulation of
senescent fibroblasts by:
1. Stimulating proliferation and cell turn over with
subsequent exhaustion of replicative life span. In
each population doubling, fibroblast telomeres
shorten approximately 50 to 100 base pairs (bp)
in culture and 15 bp per year of donor age,28
approaching a threshold telomere length with
each cell division. Several cytokines and growth
factors with stimulatory effects on fibroblast pro-
liferation, such as transforming growth factor b -
1 (TGF-b -1)30 and IL-1, have been detected to
be increased in venous ulcer tissues. 
2. The possibility that cytokines and/or oxygen-free
radicals delivered by leukocytes trapped and acti-
vated within the microvasculature of a venous
ulcer32-34 may induce cell death in young, active-
ly replicating fibroblasts selecting out for more
stable and resistant senescent cells.
Fibroblasts isolated from venous ulcers are at a
more progressed stage of senescence than fibroblasts
isolated from healthy skin. Whether this phenomena
is induced by extrinsic ulcer mechanisms, such as
injury or infection, or by intrinsic mechanisms, such
as chronic venous hypertension, is the question
addressed by an ongoing project in our laboratory
that is evaluating fibroblast senescence in patients
with venous reflux but no ulcers.
There was only a trend toward a correlation
between the percentage of SA-b -Gal positive cells and
the reduction of wound fibroblasts growth rates. Also,
it is difficult to explain a 2-fold to 20-fold reduction
in growth by the presence of an average of 6.3% SA-
b -Gal positive cells. A possible explanation originates
from the concept that as cells approach senescence,
cell growth rate diminishes.7,16 It is possible that a sig-
nificant proportion of wound fibroblasts isolated from
venous ulcers are approaching senescence (near senes-
cent), explaining the reduced growth rate found in
this study, but at the same time SA-b -Gal might not
be expressed in sufficient amounts by near senescent
fibroblasts to be detected by the bioassay.
CONCLUSIONS
Fibroblasts cultured from venous ulcers exhibited
more characteristics associated with senescent cells
when compared with fibroblasts isolated from unaf-
fected skin of the same patient. This implies that the
local accumulation of senescent fibroblasts within the
venous ulcer may be related to impaired healing.
We introduce a novel pathophysiologic concept to
explain the cellular mechanisms of disease in venous
ulcers. Potential different therapeutic approaches can
derive from these findings. Bypass of replicative senes-
cence has been achieved in the laboratory through
different mechanisms,28,29 and this technology could
have therapeutic implications in the management of
venous ulcers in the future.
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